Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer (NCT05528133)
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Who can join: Review the eligibility criteria below.
Location: Morton Plant Hospital - Baycare Health System — Clearwater, Florida
Age range: 18 Years
🧪 Interventions in This Study
- Genomically Guided Radiation Therapy (RADIATION)
- Genomically Guided Radiation Therapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Morton Plant Hospital - Baycare Health System — Clearwater, Florida
- Moffitt Cancer Center — Tampa, Florida
📞 Contact the Study Coordinator
Phone: (813) 745-0393
Email: Robin.Dowell@moffitt.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Triple Negative Breast Cancer
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Tucson, Arizona
- Comparison of the Breast Tumor Microenvironment — New York, New York
- Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer — Chicago, Illinois
- Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo — Mobile, Alabama
- Ribociclib and Bicalutamide in AR+ TNBC — Chicago, Illinois
- Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC — La Jolla, California
Explore by condition: All Triple Negative Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.